Jason N. Gorevic - Jul 27, 2023 Form 4 Insider Report for Teladoc Health, Inc. (TDOC)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Adam C. Vandervoort, Attorney-in-Fact
Stock symbol
TDOC
Transactions as of
Jul 27, 2023
Transactions value $
-$300,303
Form type
4
Date filed
7/28/2023, 04:09 PM
Previous filing
Jun 5, 2023
Next filing
Sep 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction TDOC Common Stock Sale -$300 K -10 K -1.65% $30.03 596 K Jul 27, 2023 Direct F1, F2

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 13, 2023.
F2 Represents the weighted average price of transactions ranging from $30.00 to $30.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.